Proqr Therapeutics Eo 04 Stock Debt To Equity
| 0PQ Stock | EUR 3.40 0.01 0.29% |
PROQR THERAPEUTICS EO 04 fundamentals help investors to digest information that contributes to PROQR THERAPEUTICS's financial success or failures. It also enables traders to predict the movement of PROQR Stock. The fundamental analysis module provides a way to measure PROQR THERAPEUTICS's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to PROQR THERAPEUTICS stock.
PROQR |
PROQR THERAPEUTICS EO 04 Company Debt To Equity Analysis
PROQR THERAPEUTICS's Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Current PROQR THERAPEUTICS Debt To Equity | 0.61 % |
Most of PROQR THERAPEUTICS's fundamental indicators, such as Debt To Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, PROQR THERAPEUTICS EO 04 is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
| Competition |
According to the company disclosure, PROQR THERAPEUTICS EO 04 has a Debt To Equity of 0.606%. This is 98.87% lower than that of the Healthcare sector and 96.87% lower than that of the Biotechnology industry. The debt to equity for all Germany stocks is 98.76% higher than that of the company.
PROQR Debt To Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses PROQR THERAPEUTICS's direct or indirect competition against its Debt To Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of PROQR THERAPEUTICS could also be used in its relative valuation, which is a method of valuing PROQR THERAPEUTICS by comparing valuation metrics of similar companies.PROQR THERAPEUTICS is currently under evaluation in debt to equity category among its peers.
PROQR Fundamentals
| Return On Equity | -0.75 | |||
| Return On Asset | -0.26 | |||
| Operating Margin | (16.95) % | |||
| Shares Outstanding | 71.43 M | |||
| Shares Owned By Insiders | 20.89 % | |||
| Shares Owned By Institutions | 41.47 % | |||
| Revenue | 3.93 M | |||
| Gross Profit | 2.4 M | |||
| EBITDA | (66 M) | |||
| Net Income | (46.56 M) | |||
| Cash And Equivalents | 75.84 M | |||
| Cash Per Share | 1.51 X | |||
| Total Debt | 34.28 M | |||
| Debt To Equity | 0.61 % | |||
| Current Ratio | 7.77 X | |||
| Book Value Per Share | 0.91 X | |||
| Cash Flow From Operations | (47.06 M) | |||
| Earnings Per Share | (0.92) X | |||
| Target Price | 24.96 | |||
| Number Of Employees | 181 | |||
| Beta | 0.22 | |||
| Market Capitalization | 207.46 M | |||
| Z Score | 3.6 |
About PROQR THERAPEUTICS Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze PROQR THERAPEUTICS EO 04's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of PROQR THERAPEUTICS using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of PROQR THERAPEUTICS EO 04 based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in PROQR Stock
PROQR THERAPEUTICS financial ratios help investors to determine whether PROQR Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in PROQR with respect to the benefits of owning PROQR THERAPEUTICS security.